Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,514.18 -2.09 -0.01%
TOPIX 1,169.89 -3.48 -0.30%
HANG SENG 22,760.24 64.23 0.28%

Despite IV Vancomycin’s Stronghold on the MRSA Antibiotic Hospital Market, Surveyed ID Specialists Report Shifting Away from



  Despite IV Vancomycin’s Stronghold on the MRSA Antibiotic Hospital Market,
  Surveyed ID Specialists Report Shifting Away from IV Vancomycin to Branded
  Agents, Including Pfizer’s Zyvox and Cubist/Novartis’s Cubicin

       BioTrends Research Group and Arlington Medical Resources Release
   TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US) Report

Business Wire

EXTON, Pa. -- July 11, 2012

BioTrends Research Group and Arlington Medical Resources (AMR) in their
TreatmentTrends: MRSA and Serious Gram-Positive Infections (US) report find
that decreasing susceptibility to IV vancomycin and preference for other
therapies that target methicillin-resistant Staphylococcus aureus (MRSA) are
among the most frequently cited factors that are driving physicians to
decrease usage of IV vancomycin for the management of MRSA infections in the
inpatient setting. In fact, nearly one-third of surveyed physicians report
prescribing less IV vancomycin over the past twelve months and 29 percent of
physicians anticipate decreasing their use of the drug for MRSA infections in
the future. Additionally, a notable share of ID specialists report a
significant increase in MRSA cases with reduced susceptibility to vancomycin
over the past two years and high treatment failure rates among patients
treated with IV vancomycin across key MRSA indications. On the contrary,
physicians report increasing their prescribing of Pfizer’s Zyvox (linezolid),
Cubist/Novartis’s Cubicin (daptomycin) and Forest/AstraZeneca/Dainippon
Sumitomo’s Teflaro (ceftaroline) for the management of MRSA infections in the
hospital.

“Rising vancomycin MICs levels among MRSA isolates together with vancomycin’s
shortcomings, present new opportunities for current and emerging therapies to
capitalize on and steal market share from the MRSA workhorse drug,” said
Associate Therapeutic Class Director of Infectious Diseases Brenda
Perez-Cheeks, Ph.D. “Competing therapies can differentiate themselves in areas
that are important to physicians, such as improved safety and tolerability and
demonstrated efficacy in difficult-to-treat infections.”

Although ceftaroline, the newest entrant to the MRSA and serious Gram-positive
infection market, has only been available for over a year, approximately half
of physicians report using the drug for treating MRSA infections in the past
twelve months and some have prescribed ceftaroline for a variety of
infections.

With respect to awareness of therapies in development for the treatment of
MRSA infections, ID specialists report the greatest awareness with products
with the longest history in development, specifically Durata’s dalbavancin,
Basilea’s ceftobiprole and The Medicines Company’s oritavancin. However, only
9 percent of physicians report awareness of Trius’ tedizolid, a
second-generation oxazolidinone, which is likely to be a significant challenge
to linezolid. With its potentially improved safety and tolerability profile
over linezolid –a physician reported unmet need for the management of MRSA
infections– it is not surprising that the majority of ID specialists are
willing to use tedizolid if it were to become available.

TreatmentTrends: MRSA and Serious Gram-Positives Infections (US) is an annual
report that provides insight into the treatment of patients with MRSA and
other Serious Gram-positive infections in the hospital setting. Research with
103 infectious diseases specialists analyzes the usage and uptake of
antibiotics for the treatment of key infections due to emerging and clinically
important Gram-positive pathogens, specifically MRSA. TreatmentTrends is a
syndicated report series that provides longitudinal information on market
dynamics, including insight into practice patterns, attitudes and perceptions,
unmet needs, and projected and current use of antibiotics in the hospital.
TreatmentTrends: MRSA and Serious Gram-Positives Infections (EU), the
companion study, tracking the usage of antibiotics to treat MRSA and other key
serious Gram-positive infections in Europe will publish in October 2012.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom market research to
pharmaceutical manufacturers competing in clinically evolving, specialty
pharmaceutical markets. For information on BioTrends publications and research
capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.
BioTrends is a Decision Resources Group company.

About Arlington Medical Resources

AMR (www.AMR-data.com) serves the market intelligence needs of the
pharmaceutical and diagnostic imaging industries. Research includes clinical
inpatient databases that directly link anti-infective drugs with
indication/procedure, formulary and stocking status tracking studies, drug
purchasing audits and diagnostic imaging procedure volume/contrast media usage
audits. AMR is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.

Contact:

BioTrends Research Group, LLC
Brenda Perez-Cheeks, Ph.D., 610-908-7255
bperez@bio-trends.com
or
Decision Resources Group
Lisa Osgood, 781-993-2606
losgood@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement